Tirofiban, eptifibatide and abciximab in minimizing CK-MB release during coronary intervention (TEAM trial)

被引：0
|
作者：
Sharma, SK
Richard, M
Kini, AS
Suleman, J
Perez, N
King, T
Fisher, EA
Reich, D
Marmur, JD
机构：
[1] Mt Sinai Hosp, New York, NY 10029 USA
[2] Mt Sinai Med Ctr, New York, NY 10029 USA
[3] Mt Sinai Sch Med, New York, NY USA
[4] Mt Sinai Med Hosp, New York, NY USA
来源：
CIRCULATION | 2000年 / 102卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3216
引用
收藏
页码：665 / +
页数：2
相关论文
共 50 条
  • [1] Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study)
    Kini, AS
    Richard, M
    Suleman, J
    Perez, N
    Lee, P
    Fisher, EA
    Kamran, M
    Marmur, JD
    Sharma, SK
    AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (05): : 526 - +
  • [2] Tirofiban, eptifibatide, and abciximab in minimizing myocardial damage during high-risk coronary intervention: Final results of the TEAM pilot trial
    Sharma, SK
    Kini, AS
    Perez, N
    Suleman, J
    Fisher, EA
    Marmur, JD
    Richard, M
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) : 73A - 73A
  • [3] Randomized comparison of tirofiban, eptifibatide, and abciximab in minimizing myocardial damage during high-risk percutaneous coronary intervention: TEAM pilot trial
    Sharma, SK
    Kini, A
    Perez, N
    Suleman, J
    Fisher, EA
    Marmur, JD
    Richard, M
    EUROPEAN HEART JOURNAL, 2002, 23 : 642 - 642
  • [4] Randomized COMparison of platelet inhibition with abciximab, TiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes - The COMPARE trial
    Batchelor, WB
    Tolleson, TR
    Huang, Y
    Larsen, RL
    Mantell, RM
    Dillard, P
    Davidian, M
    Zhang, DW
    Cantor, WJ
    Sketch, MH
    Ohman, EM
    Zidar, JP
    Gretler, D
    DiBattiste, PM
    Tcheng, JE
    Califf, RM
    Harrington, RA
    CIRCULATION, 2002, 106 (12) : 1470 - 1476
  • [5] Does prior β-blocker therapy reduce CK-MB enzyme release during coronary intervention?
    Kini, A
    Kini, S
    Vidhun, R
    Dangas, G
    Brown, E
    Shalouh, E
    Marmur, JD
    Ambrose, JA
    Sharma, SK
    AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (7A): : 19S - 19S
  • [6] Elevation of CK-MB following percutaneous coronary intervention
    Katritsis, DG
    EUROPEAN HEART JOURNAL, 2004, 25 (13) : 1180 - 1180
  • [7] Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention
    Brown, DL
    Fann, CSJ
    Chang, CJ
    AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (05): : 537 - 541
  • [8] Switch from abciximab to eptifibatide during percutaneous coronary intervention
    Wahlin, Magnus
    Albertsson, Per
    Karlsson, Thomas
    Matejka, Goeran
    Odell, Annika
    Tahmasebiepour, Farshad
    Wolmeryd, Christina
    Grip, Lars
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2009, 134 (03) : 393 - 400
  • [9] Troponin T (TNT) and creatine kinase MB (CK-MB) release following percutaneous coronary intervention (PC): Are they equivalent?
    Moore, R
    Lowe, R
    Morris, JL
    Morrison, WL
    Ramsdale, DR
    Perry, RA
    Stables, R
    HEART, 2005, 91 : A24 - A25
  • [10] Long-Term Mortality After Bolus-Only Administration of Abciximab, Eptifibatide, or Tirofiban During Percutaneous Coronary Intervention
    Marmur, Jonathan D.
    Poludasu, Shyarn
    Lazar, Jason
    Cavusoglu, Erdal
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2009, 73 (02) : 214 - 221
12345